Pharma Stocks Are Heating Up! Is Glenmark Next to Break Out?
Company Overview Glenmark Pharmaceuticals is a research-driven pharmaceutical company with operations across India, the US, Europe and emerging markets. Its portfolio includes branded formulations, generics, respiratory medicines and oncology products. Pharma Sector: The Bigger Picture The pharma sector is witnessing renewed buying interest, with stocks like Glenmark, Laurus Labs, Divi's Laboratories and other pharma companies attracting investor attention. Improving business growth, export opportunities and demand for specialty medicines are supporting sector sentiment. Why Glenmark Is in Focus Glenmark's Q2 FY27 performance highlighted strong business momentum, with approximately 20% like-for-like revenue growth. Emerging Markets revenue grew 33.2% YoY, while North America's core business grew around 31%. Its expanding oncology portfolio and international business provide additional growth opportunities. Technical View Glenmark is showing a strong bullish structure on the daily chart. The stock has rallied sharply from recent swing lows and is trading above its key moving averages. MACD remains positive, while RSI is around the bullish zone, indicating strong momentum. Key Levels: Immediate resistance: ₹2,690–2,715 Breakout confirmation: Above ₹2,715 Immediate support: ₹2,625–2,640 A sustained breakout above ₹2,715 with strong volumes could trigger another upward move. My View The bigger story is the improving momentum across the pharma sector. Glenmark is emerging as an interesting stock to watch, backed by business growth and a strong technical setup. A decisive breakout could bring fresh buying interest. Disclaimer: For educational purposes only. Not investment advice. Disclosure: The analyst or his family does not have any position in GLENMARK. GLENMARK




















